These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2185101)

  • 21. Cell proliferation and promotion in the hepatocarcinogenicity of peroxisome proliferating chemicals.
    Cattley RC; Marsman DS; Popp JA
    Prog Clin Biol Res; 1990; 340D():123-32. PubMed ID: 2196574
    [No Abstract]   [Full Text] [Related]  

  • 22. [Proliferation of peroxisomes and the hepatocarcinogenic process].
    Palut D
    Rocz Panstw Zakl Hig; 1997; 48(1):1-11. PubMed ID: 9273657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PPAR: a mediator of peroxisome proliferator action.
    Green S
    Mutat Res; 1995 Dec; 333(1-2):101-9. PubMed ID: 8538617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peroxisome proliferators activate Kupffer cells in vivo.
    Bojes HK; Thurman RG
    Cancer Res; 1996 Jan; 56(1):1-4. PubMed ID: 8548746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perplexing peroxisome proliferators.
    Citron M
    Environ Health Perspect; 1995 Mar; 103(3):232-5. PubMed ID: 7768221
    [No Abstract]   [Full Text] [Related]  

  • 26. Carcinogenesis by hepatic peroxisome proliferators: evaluation of the risk of hypolipidemic drugs and industrial plasticizers to humans.
    Reddy JK; Lalwai ND
    Crit Rev Toxicol; 1983; 12(1):1-58. PubMed ID: 6360536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth regulation by peroxisome proliferators: opposing activities in early and late G1.
    Ledwith BJ; Johnson TE; Wagner LK; Pauley CJ; Manam S; Galloway SM; Nichols WW
    Cancer Res; 1996 Jul; 56(14):3257-64. PubMed ID: 8764118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis.
    Ashby J; Brady A; Elcombe CR; Elliott BM; Ishmael J; Odum J; Tugwood JD; Kettle S; Purchase IF
    Hum Exp Toxicol; 1994 Nov; 13 Suppl 2():S1-117. PubMed ID: 7857698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Do peroxisome proliferating compounds pose a hepatocarcinogenic hazard to humans?
    Cattley RC; DeLuca J; Elcombe C; Fenner-Crisp P; Lake BG; Marsman DS; Pastoor TA; Popp JA; Robinson DE; Schwetz B; Tugwood J; Wahli W
    Regul Toxicol Pharmacol; 1998 Feb; 27(1 Pt 1):47-60. PubMed ID: 9629596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Excessive accumulation of autofluorescent lipofuscin in the liver during hepatocarcinogenesis by methyl clofenapate and other hypolipidemic peroxisome proliferators.
    Reddy JK; Lalwani ND; Reddy MK; Qureshi SA
    Cancer Res; 1982 Jan; 42(1):259-66. PubMed ID: 7053853
    [No Abstract]   [Full Text] [Related]  

  • 31. Receptor-mediated mechanisms of peroxisome proliferators.
    Green S
    Biochem Pharmacol; 1992 Feb; 43(3):393-401. PubMed ID: 1311577
    [No Abstract]   [Full Text] [Related]  

  • 32. 32P-postlabeling analysis of peroxisome proliferator-DNA adduct formation in rat liver in vivo and hepatocytes in vitro.
    Gupta RC; Goel SK; Earley K; Singh B; Reddy JK
    Carcinogenesis; 1985 Jun; 6(6):933-6. PubMed ID: 4006083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Peroxisome proliferation and nongenotoxic carcinogenesis: commentary on a symposium.
    Moody DE; Reddy JK; Lake BG; Popp JA; Reese DH
    Fundam Appl Toxicol; 1991 Feb; 16(2):233-48. PubMed ID: 2055355
    [No Abstract]   [Full Text] [Related]  

  • 34. Peroxisome proliferation in response to xenobiotics.
    DePierre JW; Sohlenius AK; Cai Y; Eriksson AM; Andersson K; Sundberg C
    Biochem Soc Trans; 1995 May; 23(2):425-9. PubMed ID: 7672435
    [No Abstract]   [Full Text] [Related]  

  • 35. Long-term effects of hypolipidemic peroxisome proliferator administration on hepatic hydrogen peroxide metabolism in rats.
    Tamura H; Iida T; Watanabe T; Suga T
    Carcinogenesis; 1990 Mar; 11(3):445-50. PubMed ID: 2311188
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationship of hepatic peroxisome proliferation and replicative DNA synthesis to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14,643) in rats.
    Marsman DS; Cattley RC; Conway JG; Popp JA
    Cancer Res; 1988 Dec; 48(23):6739-44. PubMed ID: 3180084
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Age-related susceptibility to the carcinogenic effect of the peroxisome proliferator WY-14,643 in rat liver.
    Cattley RC; Marsman DS; Popp JA
    Carcinogenesis; 1991 Mar; 12(3):469-73. PubMed ID: 1849052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The peroxisome proliferator class of non-genotoxic hepatocarcinogens synergize with epidermal growth factor to promote clonal expansion of initiated rat hepatocytes.
    James NH; Roberts RA
    Carcinogenesis; 1994 Dec; 15(12):2687-94. PubMed ID: 8001222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver.
    Reddy JK; Rao MS; Azarnoff DL; Sell S
    Cancer Res; 1979 Jan; 39(1):152-61. PubMed ID: 83907
    [No Abstract]   [Full Text] [Related]  

  • 40. Mechanism-based risk assessment of peroxisome proliferating rodent hepatocarcinogens.
    Williams GM; Perrone C
    Ann N Y Acad Sci; 1996 Dec; 804():554-72. PubMed ID: 8993573
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.